This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SRSF3 / Serine/arginine-rich splicing factor 3 · IHC design guide
Design Immunohistochemistry for SRSF3
SRSF3 shows general nuclear expression in tissue IHC (HPA tissue IHC). This guide covers paraffin-section staining, interpretation of nuclear signal, and the 2 annotated isoforms (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SRSF3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in tissue (HPA tissue IHC) | |
| Staining pattern | General nuclear staining across cell types (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, heat-mediated (datasheet A30468) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Broad expression may limit cell-type discrimination (HPA tissue IHC) | |
| Regulation | No expression regulator annotated (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope coverage unspecified (UniProt) |
Section 1
Recommended SRSF3 IHC & IF Protocols
Use the catalog antibody’s IHC-P protocol (datasheet A30468) as the starting point; the published SRSF3 tissue protocols below provide alternative retrieval and detection conditions (PMC4946124; PMC7149931; PMC9221257).
| Sample | Paraffin-embedded human Small intestinal stromal tumor tissue; fixative not specified (datasheet A30468) |
| Fixation | Image fixative and duration unreported (datasheet A30468); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Tris-EDTA pH 9.0 (datasheet A30468); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-SRSF3, 1:100 - 1:300 (datasheet A30468) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SRSF3-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: General nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 heat retrieval (datasheet A30468). If staining needs optimization, compare the published citrate pH 6.0 and Tris-EDTA pH 6 conditions (PMC4946124; PMC9221257).
Section 2
What Is the Expected SRSF3 Staining Pattern?
SRSF3 should give a predominantly nuclear pattern in paraffin-section IHC (HPA: general nuclear expression; reliability Supported). High staining is reported in adipocytes, glandular cells, hematopoietic cells, respiratory epithelial cells, glial cells and cerebellar granular-layer cells in the listed tissues (HPA: tissue IHC). Nuclear speckles and some cytoplasmic localisation are biologically possible (UniProt P84103: subcellular location). A membrane-rim pattern is unexpected (UniProt P84103: no transmembrane segment).
| Distinct nuclear chromogen in cells from an HPA high-staining tissue, with tissue structure still readable. | This fits the reported general nuclear pattern (HPA: tissue IHC, Supported). Judge localisation in individual cells as well as overall intensity; high is an HPA observation in specified cell populations, not a required score for every cell in a section (HPA: tissue IHC). |
| Signal forms a membrane rim, extracellular deposit or tissue-edge accent while nuclei remain unstained. | That distribution conflicts with the expected nuclear IHC pattern and lacks support from SRSF3 topology (HPA: general nuclear expression; UniProt P84103: no transmembrane segment). Check staining controls and section quality before calling it SRSF3. Cytoplasmic staining alone needs more care because cytoplasm is listed as a location (UniProt P84103). |
| An unexpected cell population stains more strongly than nearby expected cells. | Possible causes include nonspecific antibody binding or endogenous detection activity (general IHC practice). HPA reports low tissue RNA specificity and supplies no negative cell list, so an unlisted population is not automatically SRSF3-negative (HPA: tissue IHC). Compare nuclear localisation, morphology and a matched detection control. |
| Chromogen is diffuse across stroma, empty spaces or many compartments, obscuring nuclear boundaries. | Treat this as background until controls support a cellular pattern (general IHC practice). The supported tissue pattern is general nuclear expression, not uniform staining of extracellular space (HPA: tissue IHC). Review blocking, washing, primary concentration and detection chemistry using the antibody's IHC-P instructions. |
| No nuclear signal appears in an HPA high-staining cell population. | A failed positive control is possible; absence in one section does not establish that SRSF3 is absent from the tissue (general IHC practice; HPA: high staining in the specified population). Check specimen integrity and each IHC-P step against the catalog antibody's instructions. No target-specific fixation sensitivity is supplied by UniProt or HPA. |
💡Expected SRSF3 appearanceCall the result positive when discernible nuclear chromogen occurs in the relevant cells of an HPA high-staining tissue, with intensity judged against controls (HPA: general nuclear expression; tissue IHC). Dominant membrane-rim or extracellular staining without nuclear signal is suspect (UniProt P84103: no transmembrane segment; HPA: general nuclear expression).
| Which compartment should guide IHC interpretation? | Use nuclear staining as the primary readout (HPA: general nuclear expression). UniProt also lists nuclear speckles and cytoplasm, including speckle recruitment after YTHDC1 interaction (UniProt P84103). Do not require visible speckles in chromogenic paraffin sections or reject every cytoplasmic component solely on localisation. |
| How broadly can tissue staining occur? | HPA calls tissue RNA specificity low and reports high IHC staining across several listed cell populations (HPA: tissue IHC). These observations support a positive control chosen from those populations. The payload has no negative or low-staining tissue entries; it cannot justify naming a negative-control tissue. |
| What do the protein annotations establish? | The protein has two annotated isoforms, an RRM at residues 10–83, no signal peptide or propeptide, and a chain spanning residues 1–164 (UniProt P84103). These facts do not reveal which isoform an antibody detects or its epitope. Do not infer staining differences from epitope location without antibody-specific evidence. |
| How strong is the supplied antibody evidence? | Both listed antibodies are IHC Supported; CAB012986 is also ICC Supported (HPA: antibody validation). The supplied status is not IHC Enhanced, and no catalog-antibody dilution or retrieval condition is provided. Select detection and working conditions from the actual IHC-P instructions, then assess localisation and controls. |
| What should IF/ICC show? | HPA reports supported nucleoplasmic localisation and ICC/IF images in A-431, U-251MG and U2OS (HPA: subcellular). UniProt additionally lists nuclear speckles and cytoplasm (UniProt P84103). This is an interpretation cue for the separate IF/ICC guide, not an IF protocol or evidence that every image must show each compartment. |
| Situation | Likely cause | Next action |
|---|---|---|
| Nuclei are blank in a chosen positive-control section. | The IHC run, detection reagents or specimen may have failed (general IHC practice); HPA reports high staining only for specified tissue cell populations (HPA: tissue IHC). | Confirm that the expected cell population is present, verify the run controls, and repeat using the catalog antibody's IHC-P instructions. Do not assign a target-specific fixation cause from this payload. |
| Signal is predominantly cytoplasmic, with little nuclear staining. | This departs from HPA's general nuclear IHC pattern, although cytoplasm is an annotated location (HPA: tissue IHC; UniProt P84103). | Compare a known-positive section and detection control, then review cell boundaries and exposure or chromogen development (general IHC practice). Treat the pattern as unresolved until the controls support specificity. |
| A sharp membrane rim or extracellular deposits dominate. | The pattern is inconsistent with general nuclear IHC expression and the absence of a transmembrane segment (HPA: tissue IHC; UniProt P84103). | Inspect a matched control without primary antibody and review washing and detection steps (general IHC practice). Score SRSF3 only where a credible cellular, chiefly nuclear signal remains. |
| Brown haze hides nuclei throughout the section. | Excess background may arise from blocking, antibody concentration, washing or detection conditions (general IHC practice); haze is not the reported HPA nuclear pattern (HPA: tissue IHC). | Check the matched detection control and adjust one IHC-P condition at a time according to the antibody's instructions (general IHC practice). Reassess whether nuclear boundaries become distinguishable. |
| Unexpected cells stain while an expected population also stains. | Cross-reactivity or endogenous detection activity is possible (general IHC practice). An unexpected population is not a defined negative: HPA reports low tissue RNA specificity and no negative cell entries (HPA: tissue IHC). | Check the matched detection control and compare compartment, morphology and intensity across cell populations (general IHC practice). Avoid declaring an unlisted cell type SRSF3-negative from this dataset. |
| Fine nuclear speckles are not resolved in the chromogenic section. | UniProt lists nuclear speckles, while HPA's tissue IHC summary reports general nuclear expression without a speckle requirement (UniProt P84103; HPA: tissue IHC). | Evaluate the overall nuclear pattern and controls for IHC (HPA: tissue IHC; general IHC practice). Use the separate IF/ICC guide when subnuclear distribution is the experimental question (HPA: supported nucleoplasmic ICC/IF location). |
Experiment evidence
IHC & IF images showing SRSF3 staining
A30468 · IHCImmunohistochemical analysis of paraffin-embedded human Small intestinal stromal tumor. 1, Tris-EDTA,pH9.0 was used for antigen retrieval. 2
A30468 · IFImmunofluorescence analysis of MCF7 cells, using SFRS3 Antibody. The picture on the right is blocked with the synthesized peptide.
A03127 · IFImmunocytochemistry of SRSF3 in K562 cells with SRSF3 antibody at 2 μg/mL .
PB9509 · IFIF analysis of SFRS3 using anti-SFRS3 antibody (PB9509) and anti-Beta Tubulin antibody (M01857-3). SFRS3 was detected in immunocytochemical
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000112081-SRSF3/tissue/cerebral+cortex#imid_3444848
HPA · CerebellumHuman Protein Atlas IHC, Cerebellum. Source: https://www.proteinatlas.org/ENSG00000112081-SRSF3/tissue/cerebellum#imid_3444851
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000112081-SRSF3/tissue/colon#imid_3444774
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000112081-SRSF3/tissue/liver#imid_3444783
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB012986; green = SRSF3, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB012986; green = SRSF3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SRSF3 IHC & IF
🧪Run adipose tissue first and look for nuclear staining in adipocytes (HPA: High in adipocytes; UniProt P84103: nucleus). HPA detects SRSF3 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and do not designate any unstained cells on the positive slide as validated internal negatives (HPA: no negative rows).
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: None in HPA: SRSF3 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SRSF3 in A-431, U-251MG, U2OS, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide, an isotype control matched to the primary antibody’s host species and immunoglobulin class, and SRSF3 knockout material as a biological negative (standard IHC controls). Quench endogenous peroxidase for chromogenic detection and assess background in the adipose tissue control section (standard IHC practice; HPA: High in adipocytes).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected A30468 paraffin-section caption does not state a fixative (selected-SKU caption: fixative unreported). That caption uses Tris-EDTA at pH 9.0 for retrieval, but does not establish that this condition is required across tissues; ICC-IF images support nucleoplasmic localization, without showing that frozen sections or IF are easier (selected-SKU caption: Tris-EDTA pH 9.0; HPA subcellular: nucleoplasm). In adipose tissue, distinguish adipocyte nuclear staining from empty lipid spaces when scoring (HPA: High in adipocytes; standard IHC morphology).
HPA tissue IHC evidence for SRSF3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Adipocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: SRSF3 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced SRSF3 IHC Tips
Troubleshoot SRSF3 chromogenic IHC in paraffin sections using the catalog antibody’s tissue image and the stated cellular localization evidence.
What should I change if SRSF3 nuclear staining is weak after retrieval?
Use heat-mediated Tris-EDTA at pH 9.0 for antigen retrieval before SRSF3 chromogenic IHC (datasheet A30468). The catalog image documents this buffer for paraffin sections, followed by primary antibody at 1:200 overnight at 4°C (caption A30468). If nuclei remain faint, check that sections stayed immersed during heating and cooled consistently before changing antibody concentration (standard IHC practice). Compare any retrieval adjustment on adjacent sections with the same detection and counterstain settings, because uneven heating can imitate biological variation (standard IHC practice). Judge improvement by clearer nuclear staining across intact cells, consistent with the reported general nuclear pattern (HPA: tissue IHC).
Could fixation explain weak or uneven SRSF3 staining?
SRSF3-specific fixation sensitivity is unknown from the supplied evidence; the catalog image identifies paraffin sections but does not state their fixative (caption A30468). Record the actual fixative and fixation duration for each specimen, then compare similarly processed sections before attributing a staining difference to SRSF3 abundance (standard IHC practice). Overfixation and inconsistent fixation can alter epitope accessibility in IHC generally, but neither effect has been established specifically for this antibody (standard IHC practice). Keep retrieval at Tris-EDTA pH 9.0 during an initial fixation comparison, since that is the documented retrieval condition (datasheet A30468). Include intact internal tissue areas when judging whether a weak region reflects processing variation (standard IHC practice).
Should SRSF3 stain nuclei, speckles, or cytoplasm in paraffin sections?
Expect predominantly nuclear staining in chromogenic tissue IHC, because the tissue profile reports general nuclear expression (HPA: tissue IHC). Nucleoplasmic localization is supported by subcellular imaging, while UniProt also lists nuclear speckles and cytoplasm for SRSF3 (HPA: subcellular; UniProt P84103 localization). At brightfield resolution, avoid requiring individually resolved speckles to call a nucleus positive; assess nuclear signal against the surrounding cytoplasm and counterstain (standard IHC practice). A diffuse cytoplasmic signal alone deserves scrutiny because it does not match the reported general tissue-IHC pattern, although cytoplasmic localization is annotated (HPA: tissue IHC; UniProt P84103 localization). Compare intact cells within the same section before assigning a compartment-specific result (standard IHC practice).
Could isoforms or modifications change what this antibody detects?
SRSF3 has 2 annotated isoforms, and its RNA recognition motif spans residues 10–83 (UniProt P84103 isoforms and domains). Annotated modifications include phosphoserine at residue 5 and acetyllysine at residue 23, but the supplied antibody evidence does not map its epitope (UniProt P84103 modified residues; caption A30468). Therefore, a difference in chromogenic staining cannot by itself identify an isoform or demonstrate modification-dependent recognition (UniProt P84103 isoforms and modified residues; standard IHC interpretation). Ask for the antibody’s immunogen or epitope information before making either claim, and compare staining under the documented Tris-EDTA pH 9.0 retrieval condition (datasheet A30468). Record any condition changes alongside the section images so apparent epitope effects remain distinguishable from processing effects (standard IHC practice).
How should an IF experiment complement this IHC result?
Treat IF/ICC as a separate localization experiment: the supplied subcellular evidence supports nucleoplasmic SRSF3 and lists images from A-431, U-251MG, and U2OS cells (HPA: subcellular). For multiplex IF, pair SRSF3 with a validated marker for the cell population under study and a nuclear counterstain, then check whether signals occupy the expected cells (standard IF practice; HPA: subcellular). Choose fluorophores after inspecting tissue autofluorescence, and separate marker channels sufficiently to assess nuclear signal without bleed-through (standard IF practice). SRSF3 has no transmembrane segment, so permeabilization should provide access to its intracellular, especially nuclear, epitope; the exact antibody epitope is unspecified (UniProt P84103 topology and localization; caption A30468). Optimize IF fixation independently because the paraffin IHC caption reports no fixative (caption A30468).
How can I reduce brown background without losing nuclear signal?
First distinguish diffuse brown deposit from staining concentrated in intact nuclei, the pattern reported for SRSF3 tissue IHC (HPA: tissue IHC). Run a no-primary control, block endogenous peroxidase for the enzyme-based detection step, and inspect unstained or control sections for intrinsic pigment (standard chromogenic IHC practice). The documented primary dilution is 1:200 overnight at 4°C, with secondary antibody at 1:200 for 45 minutes at room temperature (caption A30468). If background persists, adjust blocking, washing, or detection exposure one factor at a time while preserving a comparable positive section (standard IHC practice). Avoid interpreting uniform edge staining or precipitate as SRSF3 expression without matching nuclear morphology (standard IHC practice; HPA: tissue IHC).
How should I score variable SRSF3 nuclear staining? ⚠ ANSWER MARKED FOR VERIFICATION
Define nuclei as the primary scoring compartment because the tissue-IHC profile describes general nuclear expression (HPA: tissue IHC). For a prespecified cell population, report the percentage of positive nuclei and, when intensity categories are reproducible, an H-score from 0–300 (standard IHC scoring practice). Normalize positive counts to all evaluable nuclei in that population, or report positive-cell density per mm² of viable analyzed tissue with the area stated (standard IHC quantification practice). Hold retrieval, detection, imaging, and threshold settings constant across compared sections; the documented retrieval condition is Tris-EDTA pH 9.0 (standard IHC practice; datasheet A30468). Exclude folds, necrotic areas, and poorly preserved regions by the same written rules for every specimen (standard IHC quantification practice).
When is an apparent SRSF3-positive area likely an artefact?
A credible result places signal in morphologically intact nuclei, consistent with the reported general nuclear tissue pattern and supported nucleoplasmic localization (HPA: tissue IHC; HPA: subcellular). Check whether the apparent positive cells match the population being scored; HPA reports high staining in several distinct populations, including adipocytes and hematopoietic cells (HPA: adipose tissue adipocytes; HPA: bone marrow hematopoietic cells). Strong section-edge deposits, necrotic-region staining, or signal retained in a no-primary control call for review of processing and detection before biological interpretation (standard IHC practice). Endogenous peroxidase can contribute chromogenic signal, so compare the peroxidase-blocked result with appropriate detection controls (standard chromogenic IHC practice). Cytoplasmic signal warrants compartment-level reporting rather than automatic rejection, since UniProt also annotates cytoplasmic localization (UniProt P84103 localization).
Boster reagents
Best SRSF3 / Serine/arginine-rich splicing factor 3 IHC Antibodies
Anti-SRSF3 antibodies have IHC data in human paraffin sections (A30468 image caption) and IF/ICC data in K562 and A549 cells (A03127 and PB9509 image captions); listed reactivity spans human, mouse, and rat (catalog).
Real IHC data
Anti-SFRS3 SRSF3 Antibody
Cat # A30468
Real IF data
Anti-SRSF3 Antibody
Cat # A03127
Real IF data
Anti-SFRS3/SRSF3 Antibody ®
Cat # PB9509
A30468 shows IHC in paraffin-embedded human small intestinal stromal tumor, while A03127 shows IF/ICC in K562 cells (respective image captions). PB9509 shows IF in A549 cells (PB9509 image caption).
Which to pick: For tissue IHC, choose rabbit polyclonal A30468, listed for IHC in human and mouse at 1:100–1:300 (A30468 catalog); its own paraffin-section image used Tris-EDTA pH 9 retrieval and 1:200 primary antibody overnight at 4 °C, with fixative unreported (A30468 image caption). For IF/ICC, A03127 has K562 images at 2 μg/mL, and rabbit polyclonal PB9509 has an A549 IF image at 5 μg/mL (A03127 and PB9509 image captions; PB9509 catalog). For the broadest listed species coverage among these three, choose A03127: human, mouse, and rat reactivity is listed, while its pictured IF/ICC data are from K562 cells (A03127 catalog and image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P84103 (SRSF3_HUMAN, Serine/arginine-rich splicing factor 3).
- Human Protein Atlas. SRSF3 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. SRSF3 subcellular location (ICC-IF): Localized to the nucleoplasm..
- Human Protein Atlas. SRSF3 antibody validation summary (2 antibodies).
- Expression of SRSF3 is Correlated with Carcinogenesis and Progression of Oral Squamous Cell Carcinoma. International journal of medical sciences 2016 — PMC4946124.
- SRSF3 functions as an oncogene in colorectal cancer by regulating the expression of ArhGAP30. Cancer cell international 2020 — PMC7149931.
- Effect of Selenium Treatment on Central Insulin Sensitivity: A Proteomic Analysis in β-Amyloid Precursor Protein/Presenilin-1 Transgenic Mice. Frontiers in molecular neuroscience 2022 — PMC9302600.
- Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis. Cancers 2022 — PMC9221257.
- PubMed PMID:1577277 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:14574404 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SRSF3 (Serine/arginine-rich splicing factor 3). Expected localisation Nuclear staining in tissue (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, heat-mediated (datasheet A30468). Validated IHC antibody: A30468 at 1:100 - 1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human Small intestinal stromal tumor tissue; fixative not specified (datasheet A30468); 2. Fixation: Image fixative and duration unreported (datasheet A30468); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Tris-EDTA pH 9.0 (datasheet A30468); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-SRSF3, 1:100 - 1:300 (datasheet A30468); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Broad expression may limit cell-type discrimination (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage unspecified (UniProt); Regulation: No expression regulator annotated (UniProt). Evidence: UniProt P84103, HPA tissue IHC · Supported, HPA ICC-IF · nucleoplasm., Datasheet A30468, PMC4946124, PMC7149931. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SRSF3/immunohistochemistry-ihc-guide.